Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

Moderna Faces Up to $2.25 Billion in Patent Payout After $950 Million Settlement

• Moderna will pay $950 million immediately to Arbutus Biopharma and Genevant Sciences to end all global litigation over Spikevax and mResvia.
• An additional $1.3 billion is due within 90 days if Moderna loses its appeal arguing limited liability as a government contractor.
• The total potential $2.25 billion payout equals 14% of Moderna’s 2023 revenue and 28% of its cash pile at year-end.
• Shares fell 3.97% on the news, extending a 38% year-to-date decline as investors price in fresh cash-flow risk.

The settlement closes a four-year legal fight that once threatened to block U.S. COVID-19 shot shipments.

MODERNA—Moderna said Tuesday it will book a $950 million charge in the second quarter of 2024 and warned investors that the tab could swell by another $1.3 billion if a federal appeals court rejects its argument that the U.S. government should shoulder liability for vaccine patents used under pandemic contracts.

The deal ends simultaneous lawsuits in Delaware, Texas and Germany that began in 2020 when Arbutus and its licensing partner Genevant alleged that Spikevax infringed a dozen patents covering lipid-nanoparticle (LNP) delivery systems originally developed at the University of British Columbia.

While the immediate payout consumes roughly one-fifth of Moderna’s $4.7 billion cash reserve, the bigger fear on Wall Street is that the biotech has opened the door to fresh claims from other mRNA patent holders now that the first domino has fallen.

The $950 Million Anatomy of a Truce

Under a confidential term sheet signed Monday and disclosed Tuesday morning, Moderna will transfer $475 million to Arbutus Biopharma and $475 million to Genevant Sciences within 15 business days, according to a securities filing. The companies agreed to drop all infringement claims in the United States, Germany, the Netherlands and Japan, and to forgo future royalties on Spikevax and mResvia sales.

The settlement dwarfs the $200 million Moderna set aside last year for “various legal contingencies,” forcing the company to increase its 2024 litigation reserve five-fold. Analysts at SVB Leerink estimate the charge will shave roughly $2.30 off full-year earnings per share, turning consensus 2024 EPS from $2.05 to a loss of $0.25.

Genevant, a 2017 spin-out from Novartis and Arbutus, holds exclusive rights to 230 patents covering ionizable lipids that form the outer shell of mRNA medicines. Those patents, issued between 2009 and 2019, were not licensed to Moderna when the Cambridge, Mass., biotech rushed Spikevax into clinical trials in March 2020 under Operation Warp Speed.

A government-shield gambit

Moderna’s last-ditch effort to cap damages rests on a 28 U.S.C. §1498 argument that its vaccine contracts with the Department of Defense and BARDA grant immunity because the inventions were “used by and for the government.” The U.S. Court of Federal Claims has previously upheld the defense in a 2008 case involving anthrax vaccines, but never in a pandemic setting where manufacturing volumes reached billions of doses.

If the Federal Circuit rejects that theory, Moderna must pay the extra $1.3 billion within 90 days, pushing the total cash outflow to $2.25 billion—more than the company spent on R&D in all of 2023.

Why Arbutus and Genevant Held the High Cards

Arbutus, a 2007 spin-out from Tekmira Pharmaceuticals, began accumulating LNP patents more than a decade before the COVID-19 pandemic. The company’s foundational ’069 patent, granted in 2013, covers pH-sensitive lipids that escape endosomes—an essential step for mRNA to reach cellular machinery and produce spike proteins.

Genevant, formed in 2017 to commercialize those same patents, already had licensing deals with BioNTech and CureVac that yielded mid-single-digit royalties. When Moderna refused to take a license in 2019, citing “freedom to operate” opinions from outside counsel, Genevant sent its first cease-and-desist letter weeks before the pandemic erupted.

Delaware District Judge Richard Andrews dealt Moderna a severe blow in March 2023 when he denied summary judgment and ruled that the patents were “not substantially invalid” under the Supreme Court’s Alice precedent. The judge also limited Moderna’s ability to introduce evidence that federal contracts conferred immunity, setting the stage for a May 2024 jury trial that would have sought royalties on 814 million Spikevax doses sold in the United States.

Damages models topping $10 billion

Genevant’s expert witness, former FDA economist Dr. Peter Barton Hutt, calculated a reasonable royalty at 5.5% of U.S. net sales, or $5.9 billion through 2023. Arbutus added a claim for enhanced damages—up to treble the amount—arguing willful infringement because Moderna’s own patent filings cited the same prior art. The combined exposure exceeded Moderna’s 2023 revenue of $19.3 billion, making a settlement preferable to rolling the dice with a jury.

What the Payout Does to Moderna’s Balance Sheet

Moderna closed the first quarter of 2024 with $4.7 billion in cash, marketable securities and restricted cash, down from $8.2 billion a year earlier as COVID-19 vaccine revenue collapsed. The immediate $950 million payment reduces liquidity to roughly $3.8 billion—still above the company’s minimum operating threshold of $2 billion but well below the $5.4 billion average maintained during 2022.

CFO Jamey Mock told investors on a May earnings call that Moderna expects to burn between $2.5 billion and $3 billion in 2024 as it scales up manufacturing for the RSV launch and funds 14 late-stage trials, including individualized cancer vaccines. Adding a potential $1.3 billion contingent payment would push the net cash burn above $4 billion, leaving the balance sheet “thin” by 2025, according to Moody’s analyst Michael Levesque.

Debt covenants and credit outlook

Moody’s affirmed Moderna’s Baa1 rating with a negative outlook in April, citing “heightened event risk from intellectual-property litigation.” The agency’s base case assumes no more than $1 billion in additional legal charges through 2025; the new reserve could trigger a one-notch downgrade if operating cash flow remains negative. S&P placed the company on CreditWatch negative Tuesday afternoon, estimating adjusted leverage could spike to 2.8× debt/EBITDA—above the 2.5× threshold that would strip Moderna of its investment-grade badge.

Moderna has $3.2 billion in convertible notes maturing between 2027 and 2029, but none due before 2027, giving management a two-year runway to rebuild cash if its appeal succeeds.

Could This Spark a New Wave of mRNA Royalty Demands?

Legal experts say the size of the Moderna settlement sends a “bat-signal” to other patent holders that mRNA vaccine makers are willing to pay nine-figure sums to avoid trial. BioNTech, CureVac and even Translate Bio—now owned by Sanofi—have all received unsolicited licensing inquiries from universities and biotechs holding early mRNA patents, according to filings with the U.S. Patent & Trademark Office.

“The Arbutus deal resets the royalty baseline,” said Jacob Sherkow, a patent-law professor at the University of Illinois College of Law. “Any portfolio that covers delivery, capping or nucleoside modifications now has a comp that starts at 5% of sales.”

Stanford University alone controls 11 patents covering N1-methyl-pseudouridine, the chemical modification that stabilizes mRNA and is used in both Spikevax and Pfizer-BioNTech’s Comirnaty. The university has not filed suit, but tech-transfer officers have held “exploratory” talks with at least two Asian vaccine makers, according to public meeting minutes.

Implications for next-gen vaccines

Moderna’s own RSV shot, mResvia, uses the same LNP platform as Spikevax and is expected to generate $3.5 billion in peak sales. Analysts at Jefferies estimate a 5% royalty would equal $175 million in annual payments, trimming EPS by 40 cents. CureVac, which licensed Arbutus technology for its second-generation COVID-19 vaccine, already pays 6% and has warned investors that “any upward adjustment in industry benchmarks could materially affect our cost structure.”

Is Moderna Stock Now a Value Trap or a Bargain?

Moderna shares closed Tuesday at $118.42, down 38% year-to-date and 78% below the 2021 pandemic peak of $497. The stock now trades at 2.1× book value, the lowest multiple since its 2018 IPO and a 40% discount to the Nasdaq Biotech Index median of 3.5×.

Bulls argue the selloff overstates litigation risk and ignores a pipeline of 48 programs, including a personalized cancer vaccine in Phase 3. Morgan Stanley analyst Matthew Harrison rates the stock “overweight,” modeling $6.3 billion in combined 2025 revenue from Spikevax boosters, mResvia and a new bird-flu shot, yielding an EPS rebound to $4.50 and a price target of $180.

Bears counter that the settlement proves mRNA platforms carry “perpetual royalty drag.” SVB Leerink downgraded the shares to “underperform,” slashing its discounted-cash-flow valuation to $95 after factoring a 4% blended royalty on all future products. The bear case also assumes Moderna will need to raise $2 billion in equity by 2026 to fund clinical trials, diluting existing holders by 8%.

Options market signals caution

Implied volatility on 30-day at-the-money calls spiked to 58%, the highest since January 2022, as investors hedge ahead of the appeals-court ruling expected in the first quarter of 2025. Put-call skew remains steeply negative, indicating traders are paying premium for downside protection below the $100 strike.